
ADAMAX - 1032
$90.00
Adamantane-modified Semax analog studied for BDNF/TrkB signaling and blood–brain barrier penetration.
- Purity
- >99%
- Testing
- 3rd-party
- Shipping
- Tracked, discreet
1 lab report (COA) available for this product.
About ADAMAX - 1032
Next-generation Semax analog. Enhanced BBB penetration and neurotrophic research.
Adamax is a synthetic heptapeptide analog of Semax, structurally modified with N-acetyl protection and an adamantane group at the N-terminus. These dual modifications confer significantly greater enzymatic stability and lipophilicity compared to parent Semax analogs, resulting in enhanced resistance to proteolytic degradation and improved blood-brain barrier (BBB) penetration. Adamax is studied in preclinical models for its role in BDNF upregulation, TrkB receptor sensitivity, and neurotrophic signaling — with the adamantane modification providing a more sustained CNS bioavailability profile than unmodified Semax.
Research applications
- BDNF expression modulation and TrkB receptor sensitivity research in hippocampal models
- Enhanced BBB penetration and CNS bioavailability pharmacokinetics studies
- Neurotrophic signaling and neuroplasticity pathway investigation
- HGF/c-Met receptor pathway potentiation and downstream signaling research
- Enzymatic stability and proteolytic resistance of adamantane-modified peptides
Lab reports (COA)
Independent third-party test results for ADAMAX - 1032, newest first.
| Batch | Tested | Lab | Purity | Report |
|---|---|---|---|---|
| PGB-ADMX10-1 | Jun 5, 2026 | Janoshik (PGB group test) | 99.63% | View COA |



